CSIMarket
 
Vincerx Pharma Inc   (VINC)
Other Ticker:  
 
 
Price: $0.8690 $0.02 2.235%
Day's High: $0.88 Week Perf: -7.52 %
Day's Low: $ 0.82 30 Day Perf: -86.21 %
Volume (M): 325 52 Wk High: $ 9.37
Volume (M$): $ 282 52 Wk Avg: $1.67
Open: $0.88 52 Wk Low: $0.61



 Market Capitalization (Millions $) 18
 Shares Outstanding (Millions) 21
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Vincerx Pharma Inc
Vincerx Pharma Inc is a biopharmaceutical company focused on the development and commercialization of next-generation targeted therapies for various forms of cancer. The company's mission is to provide innovative treatment options to patients with limited or no effective treatment choices. Vincerx Pharma aims to address unmet medical needs by advancing novel drug candidates through rigorous research and development processes. The company is committed to improving patient outcomes and quality of life by leveraging its expertise in precision medicine and targeted therapeutics.


   Company Address: 260 Sheridan Avenue, Suite 400 Palo Alto 94306 CA
   Company Phone Number: 800-6676   Stock Exchange / Ticker: NASDAQ VINC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Promising Advances in Cancer Therapeutics: Vincerx Pharma's Groundbreaking Research

Published Mon, Apr 8 2024 8:30 PM UTC

presents exciting developments in the field of cancer therapeutics with Vincerx Pharma's groundbreaking research. The company's presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024 and ASH 2023 have demonstrated positive preliminary data and highlighted the significant potential of their innovative compounds in combatting metastatic solid...

Vincerx Pharma Inc

Vincerx Pharma Inc Sees Surge in Share Prices Following AACR Presentation

Vincerx Pharma Inc has recently experienced a significant surge in its share prices, with a notable increase of 24.41% over the past five trading days and an impressive growth of 603.25% over the past 90 days. Currently, the company's shares on the NASDAQ are trading at a remarkable 311.1% above its 52-week average. These upward trends highlight the positive market sentiment towards Vincerx Pharma and indicate the potential for future success.
One of the major events that boosted Vincerx Pharma's reputation was its participation in the American Association for Cancer Research (AACR) Annual Meeting in 2024. During this event, the company presented preliminary Phase 1 data for their promising drug candidate, VIP236. The data showcased the drug's effectiveness in treating cancer, showcasing its potential to provide significant therapeutic benefits. VIP236 belongs to a novel class of drugs called kinase inhibitors, which target abnormalities in cellular signaling pathways associated with various cancers.

Clinical Study

Vincerx Pharma Presents Positive Phase 1 Results for VIP236 at AACR and Provides Promising Pipeline Updates at Virtual Investor Event

Published Mon, Apr 1 2024 12:01 PM UTC

The American Association for Cancer Research (AACR) Annual Meeting in 2024 hosted a significant event for Vincerx Pharma Inc, as the company presented preliminary Phase 1 data for their promising drug candidate, VIP236. Additionally, Vincerx took this opportunity to provide updates on the progress of their pipeline, including insights into the VIP943 program. This article wi...

Product Service News

A Ray of Hope: Vincerx Pharma's Enitociclib Combination Therapy Shows Promise in Lymphoma Treatment

Published Sun, Jan 7 2024 8:00 PM UTC

Vincerx Pharma's Enitociclib Shows Promise in Combating Lymphoma, According to National Institutes of Health (NIH) ReportVincerx Pharma, a leading biopharmaceutical company, recently announced the remarkable clinical efficacy of Enitociclib in combination with Venetoclax and Prednisone in lymphoma patients. The findings were reported by investigators from the prestigious Na...

Clinical Study

Revolutionary ADC Therapy VIP943 Unveiled: Vincerx Pharma Paves the Way to Precise and Safe Cancer Treatment

Published Sun, Dec 10 2023 5:00 PM UTC


Introduction
In an exciting development for the field of oncology, Vincerx Pharma Inc. presented its latest preclinical findings at the prestigious ASH 2023 conference. The company's VersAptx platform, known for its cutting-edge antibody-drug conjugate (ADC) technology, took center stage with the unveiling of the novel CD123-targeted ADC, VIP943. The poster presenta...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com